Literature DB >> 18835468

Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model.

Ke Ma1, Liang Xu, Haijuan Zhang, Shixian Zhang, Mingliang Pu, Jost B Jonas.   

Abstract

PURPOSE: To investigate the effect of brimonidine on the retinal ganglion cell survival in an optic nerve crush model.
DESIGN: Experimental animal study.
METHODS: Twenty-four Sprague-Dawley rats were divided into a study group of eight animals receiving intraperitoneal injections of brimonidine (1 mg/kg) and into a control group of 12 animals receiving intraperitoneal saline injections. All injections were performed one hour before the optic nerve crash and daily afterwards. For each animal, the right optic nerve was crushed for 60 seconds by a microclip with 40-g power. At 23 days after the optic nerve crush, the retinal ganglion cells were retrogradely labeled by injecting 3% fluorogold into both sides of the superior colliculus of the brain. At four weeks after the optic nerve crush, the animals were sacrificed. Photographs taken from retinal flat mounts were assessed for number and density of the retinal ganglion cells.
RESULTS: The retinal ganglion cell density of the right eyes with an optic nerve lesion was statistically significantly (P = .02) higher in the brimonidine study group (1281 +/- 189 cells/mm(2)) than in the control group (1060 +/- 148 cells/mm(2)). Correspondingly, the survival rate (ratio of retinal ganglion cell density in the right eye divided by cell density in the left eye) was statistically significantly (P = .027) higher in the study group than in the control group (61.0% +/- 6.0% vs 53.5+/-8.0%).
CONCLUSION: Intraperitoneal injections of brimonidine given prophylactically prior to and posttreatment daily after an experimental and standardized optic nerve crush in rats were associated with a higher survival rate of retinal ganglion cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835468     DOI: 10.1016/j.ajo.2008.08.005

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

1.  Histological observation of RGCs and optic nerve injury in acute ocular hypertension rats.

Authors:  Shuang Li; Jia-Hua Fang; Fa-Gang Jiang
Journal:  Int J Ophthalmol       Date:  2010-12-18       Impact factor: 1.779

2.  The effect of brimonidine on transepithelial resistance in a human retinal pigment epithelial cell line.

Authors:  Jung Hyun Park; Sung Joon Kim; Hyeong Gon Yu
Journal:  Korean J Ophthalmol       Date:  2010-06-05

3.  Presumed neuroprotective therapies prescribed by veterinary ophthalmologists for canine degenerative retinal and optic nerve diseases.

Authors:  Ryan G Hopper; Fabiano Montiani-Ferreira; Jorge da Silva Pereira; Michele C Fritz; Vickie J Ruggiero; John S Sapienza; Kumiko Kato; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2021-03-07       Impact factor: 1.644

4.  A practical approach to optic nerve crush in the mouse.

Authors:  Justin P Templeton; Eldon E Geisert
Journal:  Mol Vis       Date:  2012-07-27       Impact factor: 2.367

5.  Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.

Authors:  Yi Dai; James D Lindsey; Karen X Duong-Polk; Panida Chindasub; Christopher Kai-Shun Leung; Robert N Weinreb
Journal:  BMC Ophthalmol       Date:  2013-06-27       Impact factor: 2.209

6.  Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons.

Authors:  Wendi S Lambert; Lupe Ruiz; Samuel D Crish; Larry A Wheeler; David J Calkins
Journal:  Mol Neurodegener       Date:  2011-01-13       Impact factor: 14.195

7.  Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation.

Authors:  Y Fujita; A Sato; T Yamashita
Journal:  Cell Death Dis       Date:  2013-08-08       Impact factor: 8.469

8.  AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation.

Authors:  Yonju Ha; Wei Liu; Hua Liu; Shuang Zhu; Fan Xia; Julia E Gerson; Nisha A Azhar; Ronald G Tilton; Massoud Motamedi; Rakez Kayed; Wenbo Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-09-04       Impact factor: 4.799

9.  A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Rosario Amato; Salvatore Pezzino; Roberta Corsaro; Paola Bagnoli; Dario Rusciano
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 10.  Critical assessment of implantable drug delivery devices in glaucoma management.

Authors:  Dharani Manickavasagam; Moses O Oyewumi
Journal:  J Drug Deliv       Date:  2013-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.